

Christina Antza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/78814/publications.pdf>

Version: 2024-02-01

44
papers

620
citations

623734

14
h-index

642732

23
g-index

45
all docs

45
docs citations

45
times ranked

882
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1427-1440.	0.5	86
2	Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 311-319.	2.8	46
3	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1441-1455.	0.5	44
4	Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Nutrition</i> , 2021, 83, 111092.	2.4	41
5	Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 397-407.	1.9	29
6	Comparison of the SphygmoCor XCEL device with applanation tonometry for pulse wave velocity and central blood pressure assessment in youth. <i>Journal of Hypertension</i> , 2019, 37, 30-36.	0.5	27
7	Subclinical Arterial Damage in Children and Adolescents with Type 1 Diabetes: A Systematic Review and Meta-analysis. <i>Pediatric Diabetes</i> , 2019, 20, 668-677.	2.9	25
8	Arterial stiffness in children and adolescents with masked and sustained hypertension. <i>Journal of Human Hypertension</i> , 2021, 35, 85-93.	2.2	24
9	Overview of Systematic Reviews of Non-Vitamin K Oral Anticoagulants in Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004769.	2.2	21
10	Hypertension in Obesity: Novel Insights. <i>Current Hypertension Reviews</i> , 2020, 16, 30-36.	0.9	21
11	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. <i>International Journal of Cardiology</i> , 2021, 345, 119-124.	1.7	19
12	Masked and white coat hypertension, the double trouble of large arteries: A systematic review and meta-analysis. <i>Journal of Clinical Hypertension</i> , 2020, 22, 802-811.	2.0	17
13	Markers of Early Vascular Ageing. <i>Current Pharmaceutical Design</i> , 2017, 23, 3200-3204.	1.9	17
14	<p></p>The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2985-2996.	4.3	14
15	Body composition and arterial stiffness in pediatric patients with chronic kidney disease. <i>Pediatric Nephrology</i> , 2019, 34, 1253-1260.	1.7	14
16	Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score. <i>American Journal of Hypertension</i> , 2018, 31, 1197-1204.	2.0	13
17	Comparison Among Recommendations for the Management of Arterial Hypertension Issued by Last US, Canadian, British and European Guidelines. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 9-16.	2.2	12
18	Masked hypertensives: A disguised arterial stiffness population. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1473-1480.	2.0	12

#	ARTICLE	IF	CITATIONS
19	American, European and international hypertension guidelines: Time to shake hands?. <i>International Journal of Cardiology: Hypertension</i> , 2021, 8, 100075.	2.2	12
20	A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension. <i>Journal of Human Hypertension</i> , 2019, 33, 188-201.	2.2	11
21	The flipside of hydralazine in pregnancy: A systematic review and meta-analysis. <i>Pregnancy Hypertension</i> , 2020, 19, 177-186.	1.4	11
22	Obesity-Induced Hypertension: New Insights. <i>Current Pharmaceutical Design</i> , 2017, 23, 4620-4625.	1.9	10
23	Screening for Malnutrition Among People Accessing Health Services at Greek Public Hospitals: Results From an Observational Multicenter Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 42, 014860711772274.	2.6	9
24	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. <i>Journal of Hypertension</i> , 2020, 38, 377-386.	0.5	7
25	Reduction in environmental noise during COVID-19 pandemic and cardiovascular disease: A mystery for further investigation. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1947-1948.	2.0	7
26	Mobile Clinical Decision Support System for the Management of Diabetic Patients With Kidney Complications in UK Primary Care Settings: Mixed Methods Feasibility Study. <i>JMIR Diabetes</i> , 2020, 5, e19650.	1.9	7
27	Sleep behaviours and associated habits and the progression of pre-diabetes to type 2 diabetes mellitus in adults: A systematic review and meta-analysis. <i>Diabetes and Vascular Disease Research</i> , 2022, 19, 147916412210888.	2.0	7
28	Obesity and season as determinants of high blood pressure in a school-based screening study. <i>Journal of Human Hypertension</i> , 2019, 33, 277-285.	2.2	6
29	Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 48-54.	1.2	6
30	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. <i>Lipids in Health and Disease</i> , 2020, 19, 114.	3.0	6
31	Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis. <i>Endocrine-Related Cancer</i> , 2021, 28, 325-335.	3.1	6
32	Unmasking hypertension in children and adolescents with sickle/beta-thalassemia. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1444-1449.	2.0	5
33	Blood pressure response to noise in children and adolescents. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1442-1443.	2.0	4
34	The challenge of simplifying blood pressure screening in children and adolescents. <i>Journal of Clinical Hypertension</i> , 2020, 22, 876-878.	2.0	4
35	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. <i>Endocrine</i> , 2022, 76, 324-330.	2.3	4
36	Evaluation of subclinical cardiac damage in biopsy-proven nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2021, 34, 424-430.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Risk Models and Scores of Cardiovascular Disease in Patients with Diabetes Mellitus. Current Pharmaceutical Design, 2021, 27, 1245-1253.	1.9	3
38	Non-Vitamin K Antagonist Oral Anticoagulants in Pulmonary Embolism: An Overview of Systematic Reviews. Current Pharmaceutical Design, 2020, 26, 2686-2691.	1.9	3
39	Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap. Current Pharmaceutical Design, 2021, 27, 1068-1079.	1.9	2
40	Legacy effect on mortality in antihypertensive drug comparison trials. Journal of Hypertension, 2019, 37, 1532-1534.	0.5	1
41	The European and American guidelines in the detection of hypertension phenotypes: The no-deal under the light of clinical practice. European Journal of Preventive Cardiology, 2020, , 2047487320935559.	1.8	1
42	Comparative Analysis of Risk Stratification Scores in Atrial Fibrillation. Current Pharmaceutical Design, 2021, 27, 1298-1310.	1.9	1
43	Estimated Arterial Stiffness and Prediction of Vascular Aging: The Rising of a New Era. Current Pharmaceutical Design, 2021, 27, 1871-1877.	1.9	1
44	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. Current Pharmaceutical Design, 2021, 27, 2537-2544.	1.9	1